For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Kisspeptin-10: discovery, receptor and research history

Research Library › Neuropeptides

Kisspeptin-10 is a ten-amino-acid peptide corresponding to the C-terminal end of kisspeptin, the family of peptides encoded by the human KISS1 gene, and it binds the kisspeptin receptor KISS1R (formerly GPR54). The KISS1 gene was discovered in 1996 by Danny Welch’s laboratory at Penn State College of Medicine in Hershey, Pennsylvania. As of 22 Oct 2026, kisspeptin-10 is an investigational research peptide and is not approved as a drug anywhere.

Key facts

TypeEndogenous peptide fragment, 10 amino acids
Derived fromC-terminus of kisspeptin-54, a product of the KISS1 gene
Gene discovered1996, Danny Welch's laboratory, Penn State College of Medicine, Hershey, PA
ReceptorKISS1R (formerly GPR54), a G protein-coupled receptor identified in 2001
Physiological systemHypothalamic-pituitary-gonadal (reproductive) axis
Regulatory status (Oct 2026)Not approved anywhere; investigational; prohibited in males under WADA S2.2.1

Who discovered it

Kisspeptin was found by cancer researchers, not reproductive biologists. In 1996 Danny Welch’s laboratory at Penn State College of Medicine in Hershey, Pennsylvania, with J. H. Lee as first author, described KiSS-1 as a gene that suppressed metastasis in human melanoma cells [1]. The team named it after Hershey’s chocolate Kisses, a nod to the town where it was found [2, 3].

In 2001 the gene’s peptide products were matched to a previously orphan receptor, GPR54 [2]. In 2003 two independent groups, led by Stephanie Seminara in Boston and Nicolas de Roux in France, reported that loss-of-function variants in GPR54 were associated with absent or incomplete puberty in affected families [4, 5]. Those papers moved kisspeptin to the center of reproductive endocrinology.

Structure: from KISS1 to kisspeptin-10

The KISS1 gene encodes a precursor protein that is cut into several peptides known collectively as kisspeptins. The longest, kisspeptin-54, was first named metastin because of its anti-metastatic activity in cancer cell studies [2]. Shorter forms include kisspeptin-14, kisspeptin-13 and kisspeptin-10.

Kisspeptin-10 is the shortest of these: the final ten amino acids of kisspeptin-54, with the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. All kisspeptins share this C-terminal segment, which ends in an arginine-phenylalanine amide (an RF-amide motif) and is the region that engages the receptor [2, 3].

What it binds

Kisspeptin-10 is a ligand of KISS1R, a G protein-coupled receptor. In the hypothalamus, KISS1R is expressed on the neurons that release gonadotropin-releasing hormone (GnRH). Kisspeptin signaling is regarded as a key upstream regulator of the hypothalamic-pituitary-gonadal axis, the hormonal chain that runs from the hypothalamus to the pituitary gland and the gonads [2, 3].

Why it is studied

Research on kisspeptin followed two tracks. The first was cancer biology, where KISS1 was studied as a metastasis-suppressor gene [1, 2]. The second, which grew after 2003, was reproductive endocrinology, where kisspeptin peptides are used as research tools to probe how the hypothalamus controls the reproductive axis [3, 4, 5]. Kisspeptin-10 is widely used in laboratory work because it is the minimal common fragment of the kisspeptin family.

Research timeline

  • 1996: KiSS-1 identified as a melanoma metastasis-suppressor gene in Hershey, Pennsylvania [1].
  • 2001: GPR54 identified as the receptor for KISS1-derived peptides [2].
  • 2003: Two groups link GPR54 loss-of-function variants to absent or incomplete puberty [4, 5].
  • 2005: Imperial College London researchers begin human physiology studies of kisspeptin [3].

Regulatory status as of October 2026

As of 22 Oct 2026, no kisspeptin product, including kisspeptin-10, is approved as a drug in the United States or elsewhere. Kisspeptin peptides remain investigational. A synthetic KISS1R agonist, MVT-602, has been studied in a reproductive-endocrinology research program involving ovarian stimulation [6].

Kisspeptin was not among the peptides the FDA reviewed for its compounding lists in 2026 [7, 8]. On 14 Oct 2026 the FDA sent an interim compounding policy for certain peptides to the White House for review; its peptide list is not public [9].

The 2026 World Anti-Doping Agency Prohibited List names “kisspeptin and its agonist analogues” under section S2.2.1, prohibited at all times in males [10].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

What is kisspeptin-10?

Kisspeptin-10 is the ten-amino-acid C-terminal fragment shared by all peptides made from the KISS1 gene. It binds the kisspeptin receptor, KISS1R.

Who discovered kisspeptin?

Danny Welch’s laboratory at Penn State College of Medicine in Hershey, Pennsylvania, identified the KISS1 gene in 1996, while studying how melanoma spreads.

Why is it called kisspeptin?

The gene was discovered in Hershey, Pennsylvania, and its discoverers named it KiSS-1 as a tribute to Hershey’s chocolate Kisses.

What receptor does kisspeptin-10 bind?

It binds KISS1R, a G protein-coupled receptor originally known as GPR54 and matched to kisspeptin in 2001.

Is kisspeptin-10 FDA approved?

No. As of 22 Oct 2026, kisspeptin-10 is an investigational research peptide and is not approved as a drug anywhere.

Sources

  1. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88(23):1731–1737. doi:10.1093/jnci/88.23.1731. Link
  2. Harihar S, Ray S, Narayanan S, Santhoshkumar A, Ly T, Welch DR. Role of the tumor microenvironment in regulating the anti-metastatic effect of KISS1. Clin Exp Metastasis. 2020;37(2):209–223. doi:10.1007/s10585-020-10030-6. Link
  3. Comninos AN, Dhillo WS (Imperial College London). Kisspeptin: the master regulator of reproduction? The Endocrinologist (Society for Endocrinology), issue 128, Summer 2018. Link
  4. Seminara SB, Messager S, Chatzidaki EE, et al., Crowley WF Jr, Aparicio SAJR, Colledge WH. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614–1627. PMID 14573733. Link
  5. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA. 2003;100(19):10972–10976. PMID 12944565. Link
  6. Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation. Fertil Steril. 2024 Jan (epub 3 Nov 2023). PMID 37925096. Link
  7. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 "do not compound" list. 16 Apr 2026. Link
  8. Eglovitch JS. FDA advisory committee backs two more peptides, rejects one for compounding list. Regulatory Focus (RAPS), 24 Jul 2026. Link
  9. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
  10. World Anti-Doping Agency. 2026 Prohibited List (S2.2.1 testosterone-stimulating peptides in males). Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top